Rubra Medicaments Ltd - 531099 - Closure of Trading Window
Intimation of closure of Trading Window30-09-2021
30-09-2021
Rubra Medicaments Ltd - 531099 - Reg. 34 (1) Annual Report
Annual Report for the year ended March 31, 2021 along with AGM Notice schedule to be held on September 30, 202103-09-2021
RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Outcome for Outcome Of Board Meeting
To Consider and approved Unaudited Standalone Financial Results along with limited review report for the quarter ended June 30, 202113-08-2021
Rubra Medicaments Ltd - 531099 - Board Meeting Intimation for The Meeting Of Board Of Directors Of The Company Will Be Held On Friday, August 13, 2021
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 ,inter alia, to consider and approve 1. Standalone Unaudited Financial Results along with limited review report of the Company for the quarter ended June 30, 2021. 2. To fix the dates of Book Closure for Annual General Meeting. 3. To decide the time, venue and date of Annual General Meeting.02-08-2021
RUBRA MEDICAMENTS LTD. - 531099 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayRUBRA MEDICAMENTS LTD. 2CINL74110MH1991PLC326598 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Ritu Chhatani Designation: Company Secretary EmailId: rubraltd@gmail.com Name of the Chief Financial Officer: Abha Kapoor Designation: CFO EmailId: rubraltd@gmail.com Date: 28/07/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.28-07-2021
RUBRA MEDICAMENTS LTD. - 531099 - Shareholding for the Period Ended June 30, 2021
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here06-07-2021
RUBRA MEDICAMENTS LTD. - 531099 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Chief Financial Officer06-07-2021
Rubra Medicaments Ltd - 531099 - Closure of Trading Window
The Trading Window for dealing in the Company''s Equity Shares will remain closed from Thursday, July 1, 2021 for all Designated Employees of the Company. The closure is in connection with the declaration of financial results of the Company for the quarter ending June 30, 2021.30-06-2021
RUBRA MEDICAMENTS LTD. - 531099 - Disclosure On Related Party Transactions For The Year Ended March 31, 2021
Disclosure on Related Party Transactions for the year ended March 31, 202129-06-2021
RUBRA MEDICAMENTS LTD. - 531099 - Outcome Of Board Meeting
To considered and approved the Audited Standalone Financial Results for the year ended March 31, 202129-06-2021